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Abstract: HIV infections show great variation in the rate of progression to disease, and the 
role  of  viral  genetic  factors  in  this  variation  had  remained  poorly  characterized  until 
recently.  Now  a  series  of  four  studies  [1–4]  published  within  a  year  has  filled  this 
important gap and has demonstrated a robust effect of the viral genotype on HIV virulence. 
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Infection  with  Human  Immunodeficiency  Virus  Type  1  (HIV-1)  is  nearly  always fatal without 
treatment; however, the time from infection to death varies from less than one year to more than two 
decades  [5,6].  Uncovering  the  factors  behind  this  variation  in  HIV  virulence  (rate  of  disease 
progression) might provide important clues for the understanding and management of the disease. 
There  are  three  main  sources  of  the  variation:  host  genetic  factors,  viral  genetic  factors  and 
environmental variability—with potential interactions between the categories. In recent years, great 
effort has been put into elucidating and quantifying the role of host genetic factors [7–12]; however, 
systematic studies on the contribution of viral genetic factors had remained scarce. Hints for the role of 
viral factors included differences in virulence based on viral subtype [13–15], co-receptor use [16–19], 
or the presence of deleterious mutations in the virus [20,21]. However, the extent of heritable variation 
in HIV virulence, and its relevance in the epidemic, can only be assessed quantitatively by inspecting 
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transmission pairs or networks. Two early reports on transfusion-associated infections demonstrated 
that the rate of disease progression between donors and recipients was correlated within transmission 
pairs  [22,23].  However,  transmission  pairs  are  rarely  identified,  and  the  next  study  of  this  kind 
followed after a gap of 10 years [24], and was already from the HAART (Highly Active Antiretroviral 
Therapy) era. Because effective antiretroviral therapy is able to halt or slow disease progression, HIV 
virulence now needs to be characterized by proxies, such as plasma virus load, that are correlated with 
the  rate  of  progression  in  untreated  infections  [25].  The  study  of  Tang  et  al.  found  a  significant 
correlation of log10 HIV-1 RNA levels between transmitting (source) and seroconverting (recipient) 
heterosexual  partners  in  Zambia  [24],  which  was  consistent  with  the  earlier  findings  of  the  
pre-HAART  era.  Then  last  year  witnessed  a  breakthrough  with  the  publication  of  four  new  
studies [1–4], which all reported the correlation of virus load in phylogenetically linked transmission 
pairs,  thus  robustly  corroborating  the  effect  of  viral  genetic  factors  on  HIV  virulence.  Below  we 
describe the range of methods and study populations investigated in these studies (Table 1), and then 
discuss the interpretation and implications of the results. For completeness, we include also the earlier 
study of Tang et al. [24] in our discussion. 
Table 1. Studies that estimated the heritability of HIV virus load. 
Study  n 
Route of 
transmission 
Country 
VL 
compared 
Method 
Estimated 
heritability  
[95% CI] 
Tang et al. [24]
a  115
b  HET  Z  chronic  LC  0.20
c [0.01–0.37]
d 
Hollingsworth  
et al. [1] 
97
b  HET  UG  chronic  ANOVA  0.23
e [n.a.] 
Hecht et al. [2]  24
b  MSM  US 
acute vs. 
chronic
f  LC  0.55
c [0.19–0.78] 
Alizon et al. [3]  134
g  MSM  CH  chronic  PCA  0.59
h [0.45–0.73] 
van der Kuyl et al. 
[4] 
56
b  HET, MSM  NL 
acute vs. 
chronic
f 
LC  0.25
c [−0.01–0.48]
d 
Abbreviations: VL—virus load; HET—heterosexual; MSM—men having sex with men; LC: linear correlation;  
ANOVA: analysis of variance; PCA—phylogenetic comparative approach; n.a.: not available.  
Countries: Z—Zambia, US—United States, UG—Uganda, NL—the Netherlands, CH—Switzerland. 
a This earlier study was included for completeness. 
b Number of transmission pairs. 
c Correlation coefficient. 
d Calculated with Fisher Transformation using the point estimate and sample size. 
e Coefficient of determination. 
f Acute virus load in the secondary case was correlated with chronic virus load in the index patient. 
g Number of patients. 
h Phylogenetic signal [26]. 
 
Four  of  the  five  studies  investigated  the  correlation  of  virus  loads  within  transmission  pairs 
[1,2,4,24]. Such pairs were identified either as HIV-1 serodiscordant couples with subsequent HIV 
transmission  [1,24]  or  by  contact  tracing  of  individuals  with  recent  acute  infection  [2,4];  close 
relatedness of viruses between source and recipient was validated by phylogenetic analyses in all Viruses 2011, 3                                       
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studies.  The  ―heritability‖  of  virus  load,  or  couple  effect,  was  assessed  by  Pearson  correlation 
coefficient, r, between the virus loads of source and recipient individuals [2,4,24], or by general linear 
models  controlling  for  potential  confounders  [2,24].  Hecht  et  al.  reported  that  the  couple  effect 
remained significant when controlling for age, ancestry and human leukocyte antigen (HLA) class I 
alleles, and none of the co-factors had significant effect [2]; Tang et al. also estimated very similar 
coefficients with Pearson correlation and with general linear models controlling for age, gender and 
HLA class I markers [24]. In contrast, Hollingsworth et al. used analysis of variance (ANOVA) to 
estimate the proportion of variance in the virus loads that could be explained by similarity within 
transmission pairs [1]. Finally, Alizon et al. applied the phylogenetic comparative approach (PCA 
[26]) to estimate a ―phylogenetic signal‖, which correlates similarity in the virus loads with similarity 
(relatedness) between viral sequences within an epidemiologically linked cluster of individuals [3]. 
This  approach  does  not  require  knowledge  of  transmission  pairs,  but  works  best  with  clusters  of 
individuals who are not far removed in the transmission network. 
In  spite  of  the  differences  in  methodology,  the  estimates  from  all  studies  can  be  brought  to  a 
common ground. The relevant quantity to be estimated is the proportion of variance in the virus load 
that is explained by viral genetic factors (i.e., heritability [27]). Assuming that the similarity within 
transmitting pairs arises from the similarity of the viral genotypes, the coefficient of determination 
from ANOVA provides a robust estimate of this proportion [1]. It can also be shown that the Pearson 
correlation coefficient equals the coefficient of determination, provided the virus loads of source and 
recipient  individuals  are  normally  distributed  with  identical  variance  [1,28];  this  equivalence  was 
validated numerically on the data analyzed in  [1]. Finally, the phylogenetic signal correlates very 
strongly with heritability, with nearly identical expected values at low to moderate heritability [3]. 
Thus,  the  coefficients  derived  by  all  three  methods  (and  all  five  papers)  provide  numerically 
comparable estimates of the heritability of HIV virulence. 
The finding of considerable heritability in all five studies that encompassed five different countries 
across  three  continents,  with  patient  cohorts  characterized  by  European  [2–4]  or  African  [1,24] 
ancestry, subtype B [2–4], C [24] or A and D [1], and heterosexual [1,24] or same-sex [2,3] exposure, 
argues strongly for a robust effect of viral genetic factors in HIV virulence. Why then are the estimates 
of heritability so different among the studies? The selected main results of the studies (Table 1) show 
three-fold variation in the magnitude of heritability, and there is even greater variation if the results for 
alternative patient subsets or virus load definitions are considered. A great part of this variation might 
simply reflect the random deviation of the estimates: all studies involved relatively small samples, and 
due to the heterogeneity of the datasets, some estimates were based on subsamples. Of note, the 95% 
confidence interval of the estimate by Hecht et al. (0.19–0.78) [2] includes the point estimates of the 
other four studies. However, some of the variation might reflect systematic differences or confounding 
factors. Below, we discuss some possible sources of such variation. 
Calculation of Virus Load in the Recipient. First, the studies differed in the definition or calculation of 
the virus load in the recipients. Three studies [1,3,24] estimated ―set point‖ (i.e., chronic) virus load 
that  is  attained  after  the  resolution  of  primary  infection,  and  has  been  shown  to  correlate  with 
subsequent disease progression [25]. In contrast, two studies [2,4] used the magnitude of the acute 
peak of virus load in the recipient patient, which is also a prognostic marker for the subsequent course Viruses 2011, 3                                       
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of infection [29]; however, even these studies likely had measures of chronic virus load from most of 
the  source  individuals.  Because  different  viral  factors  might  act  (and  with  different  relative 
contribution)  during  acute  and  chronic  infection,  one  could expect  a  stronger correlation between 
chronic-chronic than between chronic-acute virus loads. This expectation was borne out in the study of 
Hecht et al., where the correlation was stronger when chronic virus loads were considered (r = 0.71 vs. 
0.55 in the chronic-acute analysis) [2]. In contrast, van der Kuyl et al. found a stronger correlation 
(r = 0.29) when recipients were in early acute infection (Fiebig stages III or IV, generally less than 30 
days after viral transmission [30]), compared when recipient virus loads were assayed in later stages of 
infection (Fiebig stages V, greater than 30 days after transmission, or VI, greater than 100 days after 
transmission) (r = 0.06) [4]. However, none of the datasets analyzed were sufficiently large to address 
this issue with any degree of confidence. 
Calculation of Virus Load in the Source. Second, the definition of set point or chronic virus load in the 
source individuals might also be relevant. Hollingsworth et al. [1] and Alizon et al. [3] used the mean 
of several measurements (where available); in addition, the latter included only individuals in whom 
fluctuations of the virus load remained within a 10-fold range. Tang et al. used a single chronic data 
point from each individual [24]. Finally, Hecht et al. [2] and van der Kuyl et al. [4] used a single virus 
load from the source (probably also in chronic stage in most cases), matched in time as closely as 
possible to the acute data point of the recipient. The definition of the chronic virus load might affect 
heritability estimates depending on the nature of the within-host evolution of HIV. Given the great 
evolutionary capacity of the virus, if genetic factors affect virulence, these might also change during 
the course of an infection [31–33]. If these changes are primarily host-specific, then adaptation to one 
host might be neutral or even maladaptive in another. In this case, the apparent heritability of virulence 
would decrease with the age of infection in the source, even though the effect of viral genetic factors 
does not. For example, immune escape mutations might generate increasing virulence in an individual; 
however, these mutations might be disadvantageous for the virus in another host with different MHC 
alleles [34–36], and therefore the host-specific component of increased virulence would be annulled or 
even reversed in recipients. In contrast, if the within-host evolution of virulence factors is primarily 
not host-specific, then heritability should be highest when the virus loads of source and recipient are 
sampled as close in time as possible, minimizing the evolutionary divergence between the two virus 
populations. Both Hecht et al. and van der Kuyl et al. used virus loads close to the transmission event; 
however, one of these studies [2] found relatively strong, the other [4] relatively weak heritability: it is 
therefore  not  possible  to  infer  the  nature  of  within-host  evolution  from  these  results.  Finally,  if  
within-host evolution has negligible effect on viral virulence factors, then the viral component of 
virulence stays constant during the course of an infection, and the time of sampling should not matter. 
In this case, highest heritability would be expected when the mean of several data points is used (as in 
[1,3])  or  when  several  measurements  are  considered  in  a  repeated  measures  analysis  [27].  These 
approaches reduce, or control for, the effect of random variation on the measurements, which would 
result in a stronger relative effect of viral genetic variation and hence greater heritability. The nature of 
within-host virulence evolution (host-specific, generic, negligible) could thus be gleaned by comparing 
heritability  estimates  calculated  using  different  definitions  of  the  virus  load  (earliest,  closest  to 
transmission or mean/repeated measures) in the same patient population. Viruses 2011, 3                                       
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Non-Viral Factors. Third, several non-viral confounding factors might bias the heritability estimates 
towards both under- and overestimation. Shared environmental factors within transmission pairs (or 
among closely related cases in [3]) might result in the overestimation of heritability. Any non-viral 
factor  that  correlates  within  transmission  pairs  increases  the  ―couple  effect‖,  which  has  been 
interpreted  as  heritability.  In  contrast,  imperfect  identification  of  transmission  pairs  results  in 
underestimation, because the viruses in some of the pairs might then not be closely related. Indeed, 
Hollingsworth et al. found stronger heritability when only pairs with the highest phylogenetic support 
for transmission were included in the analysis [1]. The PCA method used by Alizon et al. was shown 
to  be  robust  to  errors  in  the  phylogenetic  reconstruction  [3].  However,  the  method  found  strong 
heritability only when restricted to the densely sampled and connected MSM (men having sex with 
men) transmission group, but not when including all transmission groups. This indicates that general 
sequence similarity (relatedness) is not a good predictor of virulence factors when two virus strains are 
not closely related. Such a pattern can be expected if either virulence factors and/or the genomic 
region used for the phylogenetic reconstruction evolve quickly and under different selection pressures.  
Another confounding effect might arise from the influence of virus load on transmission, as has 
been  pointed  out  by  Tang  et  al.  [24].  Higher  virus  load  correlates  with  a  higher  probability  of 
transmission,  which  implies  that  transmitters  tend  to  have  virus  loads  above  the  average  of  the 
population  or  that  of  their  seroconverter  partners—which  was  indeed  found  in  both  studies  that 
included chronic data points from the recipient partners of transmission pairs [1,24]. This bias skews 
the distribution of non-viral factors towards the regimes supporting high virus load in the transmitters, 
and  thereby  reduces  the  relative  contribution  of  viral  genetic  factors  to  virulence—and  thus 
also heritability. 
In  principle,  the  ―dose‖  of  transmitted  virus  could  also  influence  the  outcome  of  an  infection. 
Higher virus load in the source individual might be associated with a higher transmitted dose. If a 
higher dose resulted in higher set point in the recipient, this could generate correlated set points within 
transmission  pairs  independent  of  viral  genetic  factors.  Unfortunately,  the  study  of  heritability  in 
transmission pairs cannot easily distinguish between genuine (genetic) heritability and dose effect. 
However, while dose certainly has an effect on the probability of successful transmission, its potential 
influence on the chronic virus load is much less clear. Most mathematical models of HIV dynamics 
predict that the virus load has a single ―stable‖ steady state at any given point in the course of the 
disease, determined by viral and host parameters [37,38]. This steady state is attained irrespective of 
the starting conditions, e.g., variation in the infectious dose. The stability of the steady state (set point) 
is confirmed by its resilience to perturbations, e.g., virus load tends to return to pre-treatment levels 
after the cessation of effective antiretroviral therapy [39]. However, the role of the infectious dose 
cannot be excluded completely. Some mathematical models allow for the establishment of efficient 
virus control (and an alternative low set point) if the HIV-specific CD4+ T cell response is preserved 
at the beginning of an infection [40,41]—which could, in principle, happen at a low infectious dose 
(and might be facilitated by antiretroviral treatment during acute infection  [42]). Furthermore, the 
transmitted dose might affect the peak virus load in acute infection, even if the subsequent set point is 
not affected. This could, at least partially, explain the chronic-acute virus load correlations that were 
found in some of the studies discussed [2,4]. Viruses 2011, 3                                       
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However, while there is so far no empirical evidence in support of a dose effect in HIV infection, 
some observations argue indirectly against it. It has been shown recently that most infections are 
initiated by a very low effective dose (a single viral clone in 60–80% of the cases [43,44]). Although 
there is some variation in the number of initially transmitted viral clones (1–10 clones were estimated 
in [44]), this variation is comparable in magnitude to the amplification of the viral stock in a single 
round of the viral life cycle (estimates of the basic reproductive ratio in acute HIV infection range 
between 3–34 [45,46]). Even the highest dose could thus give only a few days head start for the 
infection. Furthermore, in contrast to the estimations based on transmission pairs, the phylogenetic 
signal estimated by Alizon et al. on a loosely associated transmission network [3] is likely to have 
been insensitive to a potential dose effect. We therefore conclude that most of the available evidence 
argues against the relevance of a dose effect in the estimated heritability of the virus load. 
Inherent  Variability  of  Heritability.  Finally,  we  must  emphasize  that  heritability  is  an  inherently 
variable  measure,  rather  than  a  well-defined  characteristic  of  a  trait  within  a  species.  Heritability 
expresses the relative contribution of genotypic to phenotypic variability. This relative contribution 
depends  on  the  variability  of  both  the  genotype  and  of  the  environmental  factors  (in  this  sense 
including  also  the  host  genetic  factors)  that  affect  phenotype,  and  is  further  confounded  by  the 
interactions between the two [27]. Because of this, heritability characterizes a given population (with a 
given genotypic variance) in a given environment (with a given variance), and can vary considerably 
across populations of the same species. For example, more variability in the virus population (e.g., 
Central  Africa  vs.  Europe)  allows  for  stronger  heritability  of  viral  traits  (including  virulence);  in 
contrast, greater genetic variability in the host population could reduce their heritability (e.g., greater 
human  variability  in  Africa  vs.  Europe  could  reduce  the  heritability  of  HIV  virulence).  Shared 
environmental  factors  within  a  transmission  group  (e.g.,  potentially  among  MSM)  would  reduce 
environmental variance and thereby increase heritability. In this light, it might be relevant that the two 
studies restricted to MSM in high-income countries [2,3] found stronger heritability than those that 
included  several  risk  groups  or  were  conducted  in  low-income  countries  with  probably  greater 
environmental variability. In contrast, heterogeneity in the virus subtype might increase heritability; 
however, the only study that included several subtypes did control for their potential differences [1]. 
Partly due to the inherent complexity of heritability, it is difficult to make a meaningful comparison 
with the estimated effect of host factors [7–12] (host factors identified so far could explain about 20% 
of  the  variation  in  the  rate  of  disease  progression  [7]).  Furthermore,  the  study of viral factors  in 
transmission pairs who are infected with closely related or identical viruses would be analogous to the 
study  of  host  factors  in  identical  twins  infected  with  different  virus  variants—which  is  clearly 
impossible.  The  effect  of  host  factors  is  instead  investigated  with  a  high-resolution  mapping  of 
genomic variation in the infected individuals; however, this approach cannot detect variants that are 
rare or that have only a weak effect on disease progression. In addition, the effect of host and viral 
factors might not be independent, e.g., the effect of an MHC allele depends on the presence of the 
epitopes that it can present within the viral genome. These factors imply that the relative contribution 
of host and viral factors to the viral set point might vary and cannot be compared on the basis of the 
estimates for heritability and host effects. Viruses 2011, 3                                       
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Considering  all  potential  confounding  effects  and  the  inherently  variable  (population-specific) 
nature of heritability, the variation in the coefficients estimated across several continents, in different 
populations and with different methods, should not come as a surprise. In fact, the consistent finding of 
a heritable component of virus loads across these studies argues convincingly for a strong effect of 
viral genetic factors on HIV virulence—which has important implications. 
Implications. Heritable variation, if it affects survival or reproduction, sets the stage for the adaptive 
evolution of a trait. For HIV, we see that plasma virus load varies among individuals, is associated 
with  transmission,  and  is  heritable;  thus  the  conditions  for  adaptive  evolution  at  the  population 
(between  host)  level  are  in  place.  Based  on  the  dependence  of  both  transmission  probability  and 
(untreated)  survival  time  on  the  virus  load,  it  has  been  possible  to  estimate  the  virus  load  that 
maximizes the transmission potential of HIV [47] in the absence of treatment. The estimate is close to 
the current mean virus load in the epidemic, implying that the virulence of HIV might already have 
approached its optimum, and might not be likely to evolve toward attenuation [47]. Indeed, recent 
analyses of time trends in clinical markers of virulence in large patient cohorts have found mostly 
stable  [48–51]  or  increasing  [52–55]  virulence.  A  meta-analysis  of  time  trend  studies  found  that 
virulence has been increasing at a slowing rate over the last three decades, which is consistent with 
evolution toward an optimum [56]. 
However, the evolution of HIV might be dominated by the selection forces acting at the within-host 
level [57], in which case selection for the efficiency of between-host transmission can take only weak 
effect [32,58]. Traits affecting virulence might nevertheless be under selection also at the within-host 
level [58]. If virulence were linked directly to replication efficiency, then HIV would be expected to 
evolve toward the level of virulence associated with the rate of replication that is optimal for the virus 
within the host [59]. In contrast, if virulence is primarily a ―side effect‖, arising from a mechanism 
(e.g., generalized immune activation [60–62]) not directly linked to virus replication, then within-host 
selection might not drive the evolution of virulence [63]. 
The heritability and, therefore, evolvability of HIV virulence might also have implications for the 
optimal treatment strategies at both the individual and the population level. Human interventions can 
potentially affect the selection forces acting on virulence (e.g., by altering the effect of viral virulence 
factors on transmission and survival), and could therefore provoke an evolutionary response from the 
virus, with potentially harmful or beneficial consequences. 
Possible Mechanisms. Finally, a crucial next step will be to elucidate the viral factors that affect 
virulence. Such factors might fall into three broad categories. First, genomic variation might affect the 
replication capacity of the virus, which influences steady-state virus load through the production rate 
of virus particles. The existence of such factors is evidenced by attenuated virus clades containing 
deleterious mutations in nef [20] or in other accessory genes [21], and by the ―fitness costs‖ associated 
with drug resistance [64–66] or immune escape [35,67] mutations in the absence of drug or immune 
pressure. Second, genomic variation can also affect the ability of the virus to evade immune responses, 
which affects the steady-state virus load through the rate of clearance. Adaptation of HIV to the human 
immune response can affect virulence both within a host (reviewed in [68]) and, in the case of frequent 
host genotypes, also at the population level [69,70]. Finally, in addition to virus load, some viral Viruses 2011, 3                                       
 
 
211 
factors might also affect the ―per capita‖ pathogenicity of HIV, i.e., the ―conversion rate‖ between 
virus load and virulence. If much of the pathogenicity arises as a side effect (e.g., through chronic 
immune activation [60–62]), then the ability of the virus to induce this side effect might also vary [63]. 
A better understanding of these factors could provide important clues for the development of novel 
treatment strategies that could be aimed at mitigating the pathogenic effect of the virus. With the 
existence  of  viral  virulence  factors  firmly  established,  the  search  for  the  individual  factors 
can continue. 
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